Background: Phosphoglucomutase (PGM), a key enzyme in cellular glucose utilization and energy homeostasis, has been reported to show a relationship with oxidative stress. However, the clinical importance of PGM activity has not been investigated in patients with ischemic heart disease (IHD). The aim of the present pilot study was to clarify whether PGM activity has potential as a cardiovascular risk predictor in patients with IHD.
cute myocardial infarction (AMI) is a major cause of death and hospitalization. Recently, several new cardiac biomarkers have emerged as strong predictors of risk among AMI patients. Importantly, these biomarkers are primarily divided into 4 different pathophysiological aspects: (1) markers of myocardial damage, (2) markers of inflammation, (3) markers of thrombus, and (4) markers of coronary risk factors. Over the past few years, several studies have been made on predictive biomarkers of AMI. 1-4 However, few predictive biomarkers of AMI are currently used in simple, rapid, inexpensive, and widely employed tests in clinical practice. The requirement for a more powerful predictive biomarker is that it can be used for diagnosis evaluation and risk stratification of patients with AMI at a stage prior to onset of AMI.
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Phosphoglucomutase (PGM) is a key enzyme in the metabolic pathway catalyzing the interconversion of glucose-6-phosphate (G6P) and glucose-1-phosphate (G1P), with the latter then converted into uridine diphosphate glucose. 5-7 Several PGM isoforms (genes: PGM1 to PGM5) have been reported, 8-11 with PGM1 predominating in total PGM activity (approximately 90%). 9 PGM1 has been shown to be expressed ubiquitously, but high levels of expression are observed in particular in the heart, skeletal muscle, kidney, liver, and lungs. 11 The binding of endogenous PGM1 to Z-band alternatively spliced PDZmotif protein (ZASP)/Cypher was found to be enhanced by stress in rat cardiomyocytes; thus, the presence of PGM activity was suggested to be possibly associated with the abnormal recruitment of PGM1 at the Z-disc under stress. 12 Further, PGM activity has been reported to show a relationship with oxidative stress. 13 Thus, we examined serum PGM activity in patients with stable effort angina pectoris (EAP) and AMI. No clinical studies on PGM activity have been conducted, so that the clinical importance of PGM activity in humans remains unknown.
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The aim of the present pilot study was to explore the ability of PGM activity to predict cardiac events in a patient population admitted for chest pains suggestive of AMI. PGM activity was compared to that of established biomarkers of cardiac events, including myocardial, thrombosis, and inflammatory biomarkers.
Methods
Measurement of the PGM Activity
The blood samples were immediately centrifuged at 3,000×g for 10 min at 4°C to examine serum biomarkers. The clarified serum samples were frozen, stored at -70°C, and thawed just prior to the assay. All measurements of PGM activity were performed in duplicate; the researcher who performed the measurements was blinded to the other patient data. The activity of homogeneous cow cardiac muscle was measured in each assay as a control.
The levels of serum PGM activity were analyzed using an automated analyzer (Beckman Coulter AU 640, USA). The reagent (100 mmol/L Tris-HCl buffer (pH 8.0), 0.11 mmol/L glucose-1,6-diphosphate (G1-6DP), 2.7 U/L G6P hydrogenase (G6PD), 0.55 mmol/L NADP, 17 mmol/L G1P, 6.8 mmol/L EDTA-Mg (II), and 0.27 mmol/L N-acetylcysteine) for the measurement of PGM activity was made according to a previous study, 14 but with high quality chemicals and enzymes. After pre-incubation at 37°C, 180 μl of reagent was added to 20 μl of serum. The PGM activity was calculated based on the change in absorbance (340 nm) for 1 min due to the formation of NADPH.
Stability of Serum PGM Activity
To evaluate the stability of PGM activity, we monitored PGM activity under the following conditions: (1) the blood samples of patients with AMI were left for 1, 3, and 6 h at 24°C (ambient room temperature) before the centrifugation assay to examine the influence of standing time on measurements of PGM activity, and (2) 5 serum samples from 3 healthy adults and 2 patients with EAP were stored at 4°C, -20°C, or -70°C and measured for PGM activity after 1, 2, 3, 5, 14, and 30 days of storage to determine the effect of various storage conditions on PGM activity.
Determination of a Normal Level of PGM Activity
To determine a normal level of PGM activity in healthy adults, we evaluated the PGM activity of adults who were diagnosed as being healthy based on the specific health examinations at the Health-Science-Center, Sagamihara, Japan. The definitions for healthy adults in this study conformed to the following diagnostic criteria: for inclusion in the study, individuals had to be nonsmokers, not taking any medicine, and had to show a prescribed set of values for abdominal girth (men <85 cm, women <90 cm), body mass index (BMI; <25), serum cholesterol concentrations (triglyceride (TG) concentrations of <150 mg/dl, high-density lipoprotein cholesterol (HDL-C) concentrations ≥40 mg/dl), fasting blood sugar levels (<100), and blood pressure (systolic blood pressure <130 mmHg, diastolic blood pressure <85 mmHg). Based on these criteria, 290 consecutive healthy adults (109 men; the generational age range 30 to 70; 30 (n=49), 40 (n=98), 50 Comparisons were made between the EAP and AMI groups and between the STEMI (n=51) and NSTEMI (n=12) groups. Seven patients were excluded from the AMI analysis because of complications, such as post-VF and post-CPA, and the use of PCPS. IHD, ischemic heart disease; EAP, stable angina pectoris of effort; AMI, acute myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non-STEMI; VF, ventricular fibrillation; CPA, post-cardiopulmonary arrest; PCPS, percutaneous cardiopulmonary system. Figure 2 . Results on the stability of serum PGM activity. A total of 5 human serum samples were stored at 4°C, -20°C, and -70°C. We measured PGM activity after varying periods of storage (1, 2, 3, 5, 14 , and 30 days) following serum sampling. The PGM activity at -20°C and -70°C was stable for up to 30 days but declined between days 5 and 14 at 4°C. PGM, phosphoglucomutase. A Novel Biomarker of AMI (n=84), 60 (n=53), and 70 (n=6)) were included in this study.
PGM Activity in Patients With EAP and AMI
The PGM activity was examined in patients with EAP and AMI. We enrolled 174 consecutive EAP patients who were scheduled to receive a primary percutaneous coronary intervention (PCI) for the management of de novo lesions of a >75% diameter stenosis in a native coronary artery with the presence of typical stable effort angina, or positive results for the myocardial stress test. We also enrolled 63 consecutive AMI patients who received PCI at Kitasato University Hospital between March 2010 and January 2011 (Figure 1) . Patients with AMI who had developed shock, ventricular fibrillation, or post-cardiopulmonary arrest and had used the percutaneous cardiopulmonary system were excluded from the study. The baseline characteristics of the study subjects in the AMI and EAP groups were age; gender; the diagnoses of hypertension, dyslipidemia, and diabetes mellitus (these were obtained from medical records or the patient's history of currently or previously received medical therapy); smoking habit; and BMI. The patients with AMI divided into the severity of clinical stratifications, Killip classification 4 (cardiogenic shock) and Forrester classification subset IV (lung congestion and peripheral circulation insufficiency).
The patients with EAP received dual antiplatelet therapy (DAPT, aspirin (100 mg) and clopidogrel (300 mg)) at least 1 week before PCI, whereas the patients with AMI received DAPT just before PCI. After a coronary stent was implanted, the patient received DAPT at least 6 months after the PCI.
PGM activity was also compared between ST elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) patients to investigate the relationship between PGM activity and acute coronary thrombus. In 63 consecutive AMI patients, 51 were patients with STEMI, and the remaining 12 were patients with NSTEMI.
All local ethics committees approved the protocol; all patients gave informed consent before enrollment. The study was performed in accordance with the Declaration of Helsinki.
Blood Sampling Procedures
PGM activity was first measured for EAP patients on admission and for AMI patients on arrival at the hospital. In AMI patients, both PGM activity and creatine kinase (CK) were measured until the level of CK peaked out in order to clarify the relationship between PGM activity and CK. To evaluate coronary risk factors, the levels of estimated glomerular filtration rate (eGFR), 15 TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), 16 the ratio of eicosapentaenoic acid and arachidonic acid, 17 malonyldialdehyde LDL, 18 and hemoglobin A1c (HbA1c) were examined on admission. To compare PGM activity and well-established biomarkers including myocardial biomarkers (cardiac troponin T (TnT), 1 heart-type fatty acid-binding protein (H-FABP), 1 CK, CKMB, and aspartate aminotransferase (AST)), thrombosis biomarkers (d-dimer 19 and total plasminogen-activator inhibitor type 1 (PAI-1) 2 ), and inflammatory biomarkers (C-reactive protein (CRP) 20 and plasma pentraxin 3 (PTX3) 21 ) were also examined on admission. These blood samples were obtained before the primary PCI. Serum H-FABP was measured using the HUMAN H-FABP enzyme-linked immunosorbent assay (ELISA) kit (Hycult Biotech Inc, Netherlands), and the analytical range of this kit was 102-25,000 ng/ml for the H-FABP assay. 22 Plasma PTX3 level was measured using the Human Pentraxin3 ELISA kit (Perseus Proteomics Inc, Tokyo, Japan), and the analytical range of this kit was 0.1-20.0 ng/ml for PTX3 assay. 21, 23 Relationship Between PGM Activity and Biochemical Data To confirm the clinical importance of PGM activity, we evaluated the relationship between PGM activity and biochemical data, such as liver, lung, or kidney. For the patients with AMI, their PGM activity was compared with AST, alanine amino- transferase (ALT), alkaline phosphatase (ALP), and γ-glutamyl transpeptidase (γGTP). Indicating lung dysfunction, we evaluated the PGM activity in patients with lung congestion by X-ray and hypoxia by pulse oximeter (SpO2 <94% at room air). As for chronic kidney disease, we evaluated PGM activity by comparing it with eGFR.
Statistical Analysis
Continuous data are presented as the mean ± standard deviation, and categorical data are presented using absolute frequencies. Statistical analyses between continuous variables were performed with one-way ANOVA. Chi-square analysis or Fisher's exact probability test was used to evaluate differences in categorical variables between the groups. A probability value (P-value) of less than 0.05 was considered significant. The receiver operating characteristic (ROC) curve was constructed to assess the sensitivity and specificity of PGM activity measurements obtained at specific time points to diagnose AMI. Additionally, the area under the ROC curve (AUC) was performed. Statistical analyses were performed with JMP 6 soft- 
Results
Stability of Serum PGM Activity
The PGM activity of blood samples that had been left out for 1, 3, or 6 h at 24°C (ambient room temperature) did not significantly differ between the 3 different standing times. The PGM activity after varying periods (1, 2, 3, 5, 14, and 30 days) of storage at 4°C, -20°C, and -70°C is shown in Figure 2 .
The PGM activity at -20°C and -70°C was stable for up to 30 days but began to decline between 5 and 14 days at 4°C. Detection limit of our assay is 1.6 U/L, the intra-assay coefficient of variation (CV) variability ranged from 4.7 to 7.7%, and the inter-assay CV variability ranged from 1.5 to 5.2%.
Determination of a Normal Level of PGM Activity
Baseline physical characteristics and laboratory findings in 290 healthy adults are shown in Table 1 . The mean level of PGM activity in these healthy adults was 13.6 U/L (±4.5), and the histogram of PGM activity showed a log-normal distribution (4.5-29.3 U/L, median 12.6 U/L) (Figure 3) . Thus, based on these results, we defined a normal range of PGM activity (95% confidence interval) as from 4.8 to 29.0 U/L.
Comparisons Between the EAP and AMI Groups
The baseline characteristics of the EAP group (n=174) and the AMI group (n=63) are summarized in Table 2 . No significant differences in age, gender, the percentage of hypertension, and BMI were observed between the 2 groups. However, the percentage of dyslipidemia and diabetes mellitus was significantly higher in the AMI group than that in the EAP group. Additionally, the percentage of patients with a smoking habit (including past and current smoking) was also increased in the AMI group. In terms of premedication, few AMI patients received anti-hypertensive and anti-lipid treatment. DAPT was started just before PCI with AMI patients. Few AMI patients received DAPT before onset (only 5%), as compared with EAP patients (100%). The severity of AMI in this study, the percentages of the patients with AMI (STEMI and NSTEMI) were 16.1% of Killip 4 and 4.8% of Forrester subset IV. The PGM activity was not significantly different between Killip 4 and 1, and also not significantly different between Forrester subset IV and subset I. The laboratory findings for the patients in the EAP and AMI groups are shown in Table 3 . For each type of marker and PGM activity, the following was found: (1) markers of coronary risk factors -lipid-related biomarkers were shown to be significantly worse in the AMI group than those in EAP group. Among coronary risk factors, no significant differences were observed for eGFR and HbA1c. (2) PGM activity -the level of PGM activity in the AMI group was significantly higher than that in the EAP group. The ROC curve for PGM activity and the AMI patients is shown in Figure 4 . The AUC was 0.85, and the cutoff value of PGM activity in the AMI patient was 28.3 U/L based on the ROC curve. (3) Myocardial biomarkers -the levels of cardiac enzymes, such as CK, AST, and TnT on admission, were significantly increased in AMI patients. The median time from admission to the peak level of PGM activity was earlier than that of CK (PGM: 240.0 min, CK: 402.5 min, P<0.0001). (4) Markers of thrombus -the levels of PAI-1 in the AMI group were significantly higher than those in the EAP group. (5) Markers of inflammation -the levels of PTX3 in the AMI group were significantly higher than those in the EAP group.
Differences in PGM Activity Between Patients With STEMI and NSTEMI
In order to examine whether PGM activity is a useful marker for acute formation of coronary thrombus, PGM activity and myocardial, thrombosis, and inflammatory biomarkers were compared between patients with STEMI (n=51) and NSTEMI (n=12) ( Table 4) . PGM activity on admission was not significantly different between STEMI and NSTEMI groups; however, it tended to be higher in the STEMI group than in the NSTEMI group (P=0.0735). The levels of the myocardial biomarkers were high in both groups. Nonetheless, no significant differences in the myocardial markers were observed between the 2 groups, with the exception of higher peak CK levels in the STEMI group than in the NSTEMI group (P=0.0221). In addition, the peak PGM activity was higher in the STEMI group than in the NSTEMI group (P=0.0022).
Relationship Between PGM Activity and Biochemical Data
The levels of ALP or γGTP were not related with PGM activity in patients with EAP or AMI patients (ALP and PGM activity: r=0.15, γGTP and PGM activity: r=0.26). However, the levels of AST or ALT were related with the PGM activity (AST and PGM activity: r=0.81, ALT and PGM activity: r=0.80). High AST and ALT are revealed in AMI patients, their PGM activity was also increased. For the results of AMI patients with hypoxia as a result of lung congestion, whose PGM activity were not related with the grade of severity (r=-0.18). The markers of renal function, eGFR and PGM activity were not related (r=0.18).
Discussion
Normal Range and Stability of Serum PGM Activity
In this study, we defined a normal range of PGM activity in healthy adults representing the same generations as those of the ischemic heart disease patients and found that PGM activity was not high in healthy adults. The PGM activity in serum was shown to be stable under various storage conditions. Further, the PGM activity in AMI patients was significantly higher than that in EAP patients and healthy individuals. All serum samples were stored under conditions shown to maintain PGM activity and were measured for PGM activity under appropriate conditions.
Comparisons Between the EAP and AMI Groups
Lipid-related biomarkers were revealed to be significantly worse in the AMI group than in the EAP group. The levels of PAI-1, PTX3, myocardial biomarkers, and PGM activity were increased in the AMI patients. Moreover, PGM activity was increased in parallel with the myocardial, thrombosis, and inflammatory biomarkers. However, PGM activity did not indicate the pathophysiological progression in the stages of EAP.
Comparisons Between the STEMI and NSTEMI Groups
Acute coronary thrombus was associated with patients with STEMI. The levels of PGM activity, PAI-1, and PTX3 were not significantly different between the STEMI and NSTEMI groups. Only peak PGM activity and CK were significantly higher in the STEMI group than in the NSTEMI group, suggesting that the PGM activity was increased with the myocardial biomarkers. However, PGM activity showed a trend toward higher levels in the STEMI group than that in the NSTEMI group (P=0.07), indicating that PGM activity was not only associated with a myocardial damage, but an acute coronary thrombus.
Clinical Importance of Serum PGM Activity
In Table 3 , we indicate that PGM activity correlated with myocardial, thrombus, and inflammatory biomarkers. The median time from admission to the peak level of PGM activity was earlier than that of CK. PGM activity showed earlier normalization after PCI than that of CK. From the results of the ROC curve for PGM activity and the AMI patients, the AUC was 0.85, suggesting that PGM activity might be able to detect the early phase of myocardial damage and could potentially be used to evaluate the prognosis in patients with AMI. The severity of AMI in this study, the percentages of the patients with AMI (STEMI and NSTEMI) were 16.1% of Killip 4, and 4.8% of Forrester subset IV. The PGM activity was not significantly different between Killip 4 and 1, and also not significantly different between Forrester subset IV and subset I. In our previous study, 24 the levels of PGM activity were higher in severe cases, such as patients with AMI with cardiogenic shock. Furthermore, the high PGM activity on admission was related with mortality in 3 months. Therefore, PGM activity might be more increasing in AMI patients with cardiogenic shock.
Plaque rupture and subsequent thrombus formation trigger the occurrence of acute coronary syndrome. 25 Further, levels of d-dimer correlate well with subsequent coronary artery events. 26 The odds ratio for the d-dimer showed no significant difference between EAP and AMI in the PRIME study. 4 Moreover, increased PAI-1 expression has been reported to potentially comprise a considerable portion of thrombus enlargement. 2 In our results, PAI-1 was more sensitive in determining acute coronary thrombus than d-dimer. The levels of PGM activity and PAI-1 were high in the AMI group. Although the levels of PAI-1 and PGM activity were not different between the STEMI and NSTEMI groups, the PGM activity on admission showed a nearly significant tendency of higher levels in the STEMI group compared to that in the NSTEMI group (P=0.07). Thus, PGM activity might not be always correlated with oxidative stress or other thrombus diseases, and PGM activity might be associated with thrombus formation in the coronary artery.
A large percentage of inflammatory macrophages is a common finding in fissured or rupture plaques after the rupture of the majority of plaque lesions at the site of greatest mechanical stress, so that these sites are often the site of greatest inflammatory activity. 21 Recently, high-sensitivity CRP has become an inflammatory marker and provides important prognostic information about arteriosclerosis. 27 PTX3 is also a new biomarker for the acute-phase inflammatory response. 3 Our results showed that the levels of PTX3 were significantly higher in the AMI group than those in the EAP group, and that PGM activity was significantly higher in the AMI group. PGM activity might be associated with inflammation in the coronary artery in AMI, but not in EAP.
We have been able to detect more than 2 isoenzymes of PGM. Patients with AMI showed high PGM in which isoenzyme might derive from platelet (PGM-P), because the PGM Tables 1,3 . A Novel Biomarker of AMI in patients with AMI was concordant with platelet-derived pattern of PGM by native poly-acrylamide gel electrophoresis (PAGE). Thus, we guess PGM in patients with AMI might mainly derive from platelet. PGM exists in every organ, tissues, and cells which metabolize glucose. Patients with cardiogenic shock showed high PGM, and whose blood were analyzed by PAGE, we found 2 bands mainly, 1 band was PGM-P and the another band was a isoenzyme (PGM-O), which we guess exist in every organ, tissues, and cells which metabolize glucose. In patients with AMI without shock, the band of PGM-O was not able to found clearly, but in patients with shock, the band of PGM-O was able to be found clearly. Thus, in patients without shock including normal subjects, PGM-O might be detected as PGM within normal range with a blood test. Thus, we think that PGM increases in case of acute coronary syndrome or cardiogenic shock. PGM activity might be increased in parallel with biomarkers of myocardium, thrombus, and inflammation in patients with AMI. Hence, PGM activity might indicate myocardial damage, the formation of thrombus, and the presence of inflammation associated with coronary plaque rupture. However, further study of the PGM isoform expressed during myocardial damage, thrombus formation, and the inflammation associated with coronary plaque rupture is needed.
Study Limitations
First, the origin of PGM has not been clear. We need further study of PGM isoform expressed during myocardial damage, thrombus formation, and the inflammation associated with coronary plaque rupture and several cardiovascular diseases. Second, we do not have enough data about myocardial viability in chronic phase evaluated by the examination for left ventriculography or the association between the culprit lesion of AMI and PGM activity.
Conclusion
This pilot study suggested that PGM activity might be useful in diagnostic application in acute phase of AMI patients.
